Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$3.9M
Filings
22
Firms Hired
2
Active Period
2011–2015
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Food and Drug Administration Safety Over Sequestration Act of 2015
2015 · second_quarter · Firm: IKARIA
Deficit reduction/impact of sequestration on FDA and NIH; FDA Safety Over Sequestration Act of 2015 (HR 1078); FDA, NIH, and BARDA/CDC appropriations.
Client expense: $120,000 · Firm income: —
Matched citations: HR 1078
Protecting Seniors' Access to Medicare Act of 2015
2015 · second_quarter · Firm: IKARIA
Non-interference; rebates; Protecting Seniors' Access to Medicare Act of 2015 (S/141 HR 1190)Medicare Access and Children's Health Insurance Plans Re-Authorization Act of 2015 (HR2)
Client expense: $120,000 · Firm income: —
Matched citations: HR 1190
340B Drug Pricing Program; Critical Care; 21st Century Cures initiative; Medical Device Tax Repeal (HR160/S149); Innovation for Healthier Americans Initiative
Client expense: $120,000 · Firm income: —
Matched citations: HR160
Medicare Access and CHIP Reauthorization Act of 2015
2015 · second_quarter · Firm: IKARIA
Non-interference; rebates; Protecting Seniors' Access to Medicare Act of 2015 (S/141 HR 1190)Medicare Access and Children's Health Insurance Plans Re-Authorization Act of 2015 (HR2)
Client expense: $120,000 · Firm income: —
Matched citations: HR2
STRONG Patents Act of 2015 (S632); The Innovation Act (HR9)
Client expense: $120,000 · Firm income: —
Matched citations: HR9
Medical Device Access and Innovation Protection Act
2015 · second_quarter · Firm: IKARIA
340B Drug Pricing Program; Critical Care; 21st Century Cures initiative; Medical Device Tax Repeal (HR160/S149); Innovation for Healthier Americans Initiative
Client expense: $120,000 · Firm income: —
Matched citations: S149
STRONG Patents Act of 2015 (S632); The Innovation Act (HR9)
Client expense: $120,000 · Firm income: —
Matched citations: S632
Food and Drug Administration Safety Over Sequestration Act of 2015
2015 · first_quarter · Firm: IKARIA
Deficit reduction/impact of sequestration on FDA and NIH; FDA Safety Over Sequestration Act of 2015 (HR 1078); FDA, NIH, and BARDA/CDC appropriations.
Client expense: $310,000 · Firm income: —
Matched citations: HR 1078
Protecting Seniors' Access to Medicare Act of 2015
2015 · first_quarter · Firm: IKARIA
Non-interference; rebates; Protecting Seniors' Access to Medicare Act of 2015 (S/141 HR 1190)Medicare Access and Children's Health Insurance Plans Re-Authorization Act of 2015 (HR2)
Client expense: $310,000 · Firm income: —
Matched citations: HR 1190
340B Drug Pricing Program; Critical Care; 21st Century Cures initiative; Medical Device Tax Repeal (HR160/S149); Innovation for Healthier Americans Initiative
Client expense: $310,000 · Firm income: —
Matched citations: HR160
Medicare Access and CHIP Reauthorization Act of 2015
2015 · first_quarter · Firm: IKARIA
Non-interference; rebates; Protecting Seniors' Access to Medicare Act of 2015 (S/141 HR 1190)Medicare Access and Children's Health Insurance Plans Re-Authorization Act of 2015 (HR2)
Client expense: $310,000 · Firm income: —
Matched citations: HR2
STRONG Patents Act of 2015 (S632); The Innovation Act (HR9)
Client expense: $310,000 · Firm income: —
Matched citations: HR9
Medical Device Access and Innovation Protection Act
2015 · first_quarter · Firm: IKARIA
340B Drug Pricing Program; Critical Care; 21st Century Cures initiative; Medical Device Tax Repeal (HR160/S149); Innovation for Healthier Americans Initiative
Client expense: $310,000 · Firm income: —
Matched citations: S149
STRONG Patents Act of 2015 (S632); The Innovation Act (HR9)
Client expense: $310,000 · Firm income: —
Matched citations: S632
Critical Care Assessment and Improvement Act of 2013
2014 · fourth_quarter · Firm: IKARIA
340B Drug Pricing Program; Critical Care Assessment and Improvement Act of 2014 (S 2966/HR2651); 21st Century Cures initiative; Medical Device Tax Repeal (HR 523/S232)
Client expense: $170,000 · Firm income: —
Matched citations: HR2651
Food and Drug Administration Safety Over Sequestration Act of 2013
2014 · fourth_quarter · Firm: IKARIA
Deficit reduction/impact of sequestration on FDA and NIH; FDA Safety Over Sequestration Act of 2013 (HR 2725); FDA User Fee Protection Act (S 1413); FDA and BARDA/CDC appropriations.
Client expense: $170,000 · Firm income: —
Matched citations: HR 2725
Protecting Seniors' Access to Medicare Act of 2013
2014 · fourth_quarter · Firm: IKARIA
Non-interference; rebates; Protecting Seniors' Access to Medicare Act of 2013 (S 1316 and HR 351)
Client expense: $170,000 · Firm income: —
Matched citations: HR 351
340B Drug Pricing Program; Critical Care Assessment and Improvement Act of 2014 (S 2966/HR2651); 21st Century Cures initiative; Medical Device Tax Repeal (HR 523/S232)
Client expense: $170,000 · Firm income: —
Matched citations: HR 523
Protecting Seniors' Access to Medicare Act of 2013
2014 · fourth_quarter · Firm: IKARIA
Non-interference; rebates; Protecting Seniors' Access to Medicare Act of 2013 (S 1316 and HR 351)
Client expense: $170,000 · Firm income: —
Matched citations: S 1316
Deficit reduction/impact of sequestration on FDA and NIH; FDA Safety Over Sequestration Act of 2013 (HR 2725); FDA User Fee Protection Act (S 1413); FDA and BARDA/CDC appropriations.
Client expense: $170,000 · Firm income: —
Matched citations: S 1413
Medical Device Access and Innovation Protection Act
2014 · fourth_quarter · Firm: IKARIA
340B Drug Pricing Program; Critical Care Assessment and Improvement Act of 2014 (S 2966/HR2651); 21st Century Cures initiative; Medical Device Tax Repeal (HR 523/S232)
Client expense: $170,000 · Firm income: —
Matched citations: S232
Critical Care Assessment and Improvement Act of 2014
2014 · fourth_quarter · Firm: IKARIA
340B Drug Pricing Program; Critical Care Assessment and Improvement Act of 2014 (S 2966/HR2651); 21st Century Cures initiative; Medical Device Tax Repeal (HR 523/S232)
Client expense: $170,000 · Firm income: —
Matched citations: S 2966
Critical Care Assessment and Improvement Act of 2013
2014 · third_quarter · Firm: IKARIA
340B Drug Pricing Program; Critical Care Assessment and Improvement Act of 2013 (HR 2651); 21st Century Cures initiative; Medical Device Tax Repeal (HR 523/S232)
Client expense: $130,000 · Firm income: —
Matched citations: HR 2651
Food and Drug Administration Safety Over Sequestration Act of 2013
2014 · third_quarter · Firm: IKARIA
Deficit reduction/impact of sequestration on FDA and NIH; FDA Safety Over Sequestration Act of 2013 (HR 2725); FDA User Fee Protection Act (S 1413); FDA and BARDA/CDC appropriations.
Client expense: $130,000 · Firm income: —
Matched citations: HR 2725
Protecting Seniors' Access to Medicare Act of 2013
2014 · third_quarter · Firm: IKARIA
Non-interference; rebates; Protecting Seniors' Access to Medicare Act of 2013 (S 1316 and HR 351)
Client expense: $130,000 · Firm income: —
Matched citations: HR 351
Source: Senate LDA